α-Glucosidase inhibitor miglitol attenuates glucose fluctuation, heart rate variability and sympathetic activity in patients with type 2 diabetes and acute coronary syndrome: a multicenter randomized controlled (MACS) study.
Michio ShimabukuroAtsushi TanakaMasataka SataKazuoki DaiYoshisato ShibataYohei InoueHiroki IkenagaShinji KishimotoKozue OgasawaraAkira TakashimaToshiyuki NikiOsamu ArasakiKoichi OshiroYutaka MoriMasaharu IshiharaKoichi Nodenull nullPublished in: Cardiovascular diabetology (2017)
In T2DM patients with recent ACS, glucose fluctuations with subclinical hypoglycemia were associated with alterations of HRV and SNS activity, which were mitigated by miglitol, suggesting that these pathological relationships may be a residual therapeutic target in such patients. Trial registration Unique Trial Number, UMIN000005874 ( https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006929 ).
Keyphrases
- acute coronary syndrome
- heart rate variability
- phase iii
- phase ii
- double blind
- end stage renal disease
- heart rate
- clinical trial
- study protocol
- open label
- newly diagnosed
- type diabetes
- chronic kidney disease
- blood glucose
- placebo controlled
- percutaneous coronary intervention
- prognostic factors
- antiplatelet therapy
- minimally invasive
- cross sectional
- glycemic control
- blood pressure
- molecular docking
- metabolic syndrome
- patient reported outcomes
- insulin resistance